Drag a card by its title · ⚙ to size, swap or remove

The company

ImmuCell Corporation

ICCC · Nasdaq

Health CareDiagnostics & LabsLeading

ICCC stood above a rising 150-day average in 35 of the last 52 weekly readings, including each of the last 30 weeks. It is 14.2% above that average now. Diagnostics & Labs: 48% of its 44 stocks in an uptrend (−2 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation: Leading
Weeks in an uptrend: 30 in a row
Industry in uptrend: 48% -2 in 4 wk
Insider buys, 12 months: $248K
Insider sales, 12 months: $0
Officials’ trades on record: 0
Institutions holding: 30 (+4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 35 of 52 weeks.

17 Apr – 16 Oct

Diagnostics & Labs: About half its stocks are in an uptrend and the share has held steady. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months6

Sale orders, 12 months0

Buyers · sellers2 · 0

Who	Did	Shares	Traded
Boekhorst Paul Francis Olivier TePresident and CEO	bought	8,000at $9.50	18 Jun 2026filed 22 Jun 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders30+4 on the quarter

New · exited7 · 3

Reported value$13.4M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026	268,130$2.7M	+7,803+3.0%
MORGAN STANLEYadded · filed 13 Aug 2026	233,910$2.4M	+12,194+5.5%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026	171,089$1.7M	+19,300+12.7%
Cresset Asset Management, LLCunchanged · filed 14 Aug 2026	135,267$1.4M	00.0%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026	72,270$726K	+6,505+9.9%
DIMENSIONAL FUND ADVISORS LPadded · filed 11 Aug 2026	58,452$587K	+2,422+4.3%
Bleichroeder LPreduced · filed 13 Aug 2026	50,000$503K	-51,594−50.8%
Steadtrust LLCreduced · filed 9 Jul 2026	45,370$456K	-9,000−16.6%
Mesirow Financial Investment Management, Inc.unchanged · filed 22 Jul 2026	42,481$427K	00.0%
CITADEL ADVISORS LLCadded · filed 14 Aug 2026	40,503$407K	+4,807+13.5%

31 Mar 2023 – 30 Jun 2026

News

No headline names it lately.

Everyone who traded it

Boekhorst Paul Francis Olivier te President and CEO · last 18 Jun 20265 · 0

David Scott Tomsche Director · last 15 Apr 202629 · 0

Gloria F. Basse Director · last 15 Apr 20260 · 0

Kathy Turner V Director · last 15 Apr 20260 · 0

Paul R. Wainman Director · last 15 Apr 20268 · 0

Michael F. Brigham Director · last 20 Mar 20265 · 0

Bobbi Jo Brockmann VP of Sales and Marketing · last 27 Jan 20260 · 0

Timothy C. Fiori Chief Financial Officer · last 27 Jan 20260 · 0

Bryan K. Gathagan Director · last 12 Jun 20251 · 0

Steven T. Rosgen Director · last 16 Apr 20250 · 0

David Cunningham Director · last 15 Dec 20228 · 0

Joseph H. Crabb Former VP and CSO · last 9 Mar 20225 · 5

Same industry

TRIB Trinity BiotechLeading+97%

CDNA CareDxLeading+83%

XGN ExagenLeading+49%

NTRA NateraLeading+46%

FTRE Fortrea HoldingsLeading+41%

PSNL PersonalisLeading+35%

TKNO Alpha TeknovaLeading+32%

ADPT Adaptive BiotechnologiesLeading+20%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202541.4%

Operating profit marginFY 2025 · to 31 Dec 20256.0%

Free cash flow marginFY 2025 · to 31 Dec 20254.4%

Return on capital employedFY 2025 · to 31 Dec 20254.3%

Debt to equityFY 2025 · to 31 Dec 20250.40×

Research spendFY 2025 · to 31 Dec 202511.0%

Share count trendFY 2025 · to 24 Mar 20260.0%

Cash and equivalentsFY 2025 · to 31 Dec 2025$3.8M

Free cash flowFY 2025 · to 31 Dec 2025$1.2M

Analyst forecasts

No analyst forecasts yet.